Hypolipidemic Drugs and Lipoprotein Metabolism

  • Robert I. Levy
  • Terry Langer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 26)


Insight into the mechanism of action and efficacy of hypolipidemic drugs has awaited the development of the current concepts of lipid transport (1). Fundamental is the fact that the blood fats-- cholesterol, phospholipid, and triglyceride-- do not circulate free in the plasma. Lipids exist in a soluble form in the blood only because they are bound to protein. These proteins serve as detergents and solubilize the otherwise insoluble lipid. It is as lipid protein complexes or lipoproteins that all fat enters and leaves the blood stream.


Nicotinic Acid Lipoprotein Metabolism Hepatic Cholesterol Synthetic Rate Hypolipidemic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fredrickson, D. S., R. I. Levy and R. S. Lees. New Eng. J. Med. 276: 34 (1967).PubMedCrossRefGoogle Scholar
  2. 2.
    Fredrickson, D. S. and R. T. Levy in The Metabolic Basis of Inherited Disease. (Eds.) J. B. Stanbury, J. B. Wyngaarden and D. S. Fredrickson, McGraw-Hill, New York, in press (1972)Google Scholar
  3. 3.
    Havel, R. J., N. A. Eder and J. H. Bragdon. J. Clin. Invest. 34: 1345 (1955).PubMedCrossRefGoogle Scholar
  4. 4.
    Langer, T., W. Strober and R. I. Levy, in preparation.Google Scholar
  5. 5.
    McFarlane, A. S. Nature (London) 182: 53 (1958).CrossRefGoogle Scholar
  6. 6.
    Nosslin, B. in Metabolism of Human Gamma Globulin. (Ed.) S. B. Anderson, Blackwell Sci. Publ., Oxford (1964) p. 34.Google Scholar
  7. 7.
    Levy, R. I. and D. S. Fredrickson. Postgrad. Med. 47: 130 (1970).PubMedGoogle Scholar
  8. 8.
    Hashim, S. A. and T. B. Vanitallie. J. A. M. A. 192: 289 (1965).PubMedCrossRefGoogle Scholar
  9. 9.
    Goodman, D. S. and R. P. Noble. J. Clin. Invest. 47: 231 (1968).PubMedCrossRefGoogle Scholar
  10. 10.
    Walton, K. W., P. J. Scott, P. W. Dykes and J. W. L. Davies. Clin. Sci. 29: 217 (1965).PubMedGoogle Scholar
  11. 11.
    Kritchevsky, D. in Proceedings of the Workshop on the Metabolic Effects of Nicotinic Acid, Flims. Switzerland (1970) in press.Google Scholar
  12. 12.
    Carlson, L. A., L. Orb and J. Ostman. J. Ather. Res. 8: 667 (1968).CrossRefGoogle Scholar
  13. 13.
    Levy, R. I., D. Bilheimer and S. Eisenberg. Biochem. Soc. Symposium. In press (1972).Google Scholar
  14. 14.
    Langer, T., W. Strober and R. I. Levy. J. Clin. Invest. 48: 49a (1969).Google Scholar
  15. 15.
    Bilheimer, D. W., S. Eisenberg and R. I. Levy. A.H.A.Ahstract Circulation. Vol. 44: II - 56, 1971.Google Scholar

Copyright information

© Springer Science+Business Media New York 1972

Authors and Affiliations

  • Robert I. Levy
    • 1
  • Terry Langer
    • 1
  1. 1.Section on Lipoproteins, Molecular Disease BranchNational Heart & Lung InstituteBethesdaUSA

Personalised recommendations